Consolidated condensed statements of operations and comprehensive (loss) income - USD ($) $ in Thousands		3 Months Ended
		Apr. 02, 2022	Apr. 03, 2021
Income Statement [Abstract]
Net sales		$ 117,290	$ 81,778
Cost of sales (including depreciation and amortization of $9,218 and $5,236 respectively)		41,588	22,222
Gross profit		75,702	59,556
Selling, general and administrative expense		86,124	34,686
Research and development expense		6,928	947
Restructuring costs		577	0
Change in fair value of contingent consideration		269	0
Depreciation and amortization		3,254	1,925
Operating (loss) income		(21,450)	21,998
Interest income, net		(1,550)	(2,876)
Other expense		38	419
Other income		(1,512)	(2,457)
(Loss) income before income taxes		(19,938)	24,455
Income tax benefit		(5,132)	(73)
Net (loss) income		(14,806)	24,528
Loss attributable to noncontrolling interest		3,529	408
Net (loss) income attributable to Bioventus Inc.		(11,277)	24,936
Change in foreign currency translation adjustments		(682)	(1,156)
Comprehensive (loss) income		(15,488)	23,372
Comprehensive loss attributable to noncontrolling interest		3,669	408
Comprehensive (loss) income attributable to Bioventus Inc.		$ (11,819)	$ 23,780
Earnings Per Share [Abstract]
Loss per share of Class A common stock, basic (in dollars per share)	[1]	$ (0.19)	$ (0.02)
Loss per share of Class A common stock, diluted (in dollars per share)	[1]	$ (0.19)	$ (0.02)
Weighted Average Number Of Shares Outstanding [Abstract]
Weighted-average shares of Class A common stock outstanding - basic (in shares)	[1]	60,484,969	41,797,882
Weighted-average shares of Class A common stock outstanding - diluted (in shares)	[1]	60,484,969	41,797,882

[1] (1) Per share information for the three months ended April 2, 2021 represents loss per share of Class A common stock and weighted-average shares of Class A common stock outstanding from February 16, 2021 through October 2, 2021, the period following Bioventus Inc.'s initial public offering and related transactions described in Note 1. Organization and Note 8. Earnings per share within the Notes to the unaudited condensed consolidated financial statements.